NCT00274456 - Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer | Biotech Hunter

Enrollment

302

Participants

Timeline

Start Date

November 1, 2005

Primary Completion Date

March 1, 2008

Study Completion Date

July 1, 2011

Conditions

Metastatic Breast Cancer

Interventions

DRUG

ABI-007

ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m\^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.

DRUG

Docetaxel

Docetaxel dosed q3w at 100 mg/m\^2

Trial Locations (1)

01021

Study Sites in Russia and the Ukraine, Kiev